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Chapter   1
General introduction 
There are few drugs in oncology that are so old as 5FU,  and still  so 
widely  used.  This  molecule  has  not  been  replaced  neither  by  more  recent 
antiproliferative  agents,  nor  by  the  newly  introduced  biological  weapons. 
Rather, 5FU has remained the basis to which other agents have been added. It 
is  used,  in  combination  with  several  anticancer  drugs  and/or  with 
radiotherapy, in the treatment of different carcinomas such as colorectal, head-
and-neck, oesophageal, gastric, pancreas and breast. The possibility of using 
different schedules of administration and of combining it with anticancer drugs 
or with modulating agents resulted in a variety of clinical protocols. 
From a clinical point of view 5FU plays a major role in the treatment of 
several  carcinomas  and  it  has  been  most  extensively  studied  in  colorectal 
cancer.  For many years it actually was the only drug with a consistent activity 
in this disease and it was necessary to use it at its best.  In the last years 
results in colorectal cancer have improved thanks to the availability of new 
“traditional”  drugs  (Irinotecan,  Oxaliplatin)  and  of  monoclonal  antibodies 
(Bevacizumab, Cetuximab). 
A similar evolution of treatment is happening in head-and-neck cancer: 
5FU  and  platinum  represent  the  basis  to  which  radiotherapy,  traditional 
anticancer drugs (taxanes) and biological agents (Cetuximab) have been added. 
Several reviews have been published on the general mechanism of action, 
biochemistry and pharmacology of 5FU. 
Fluorinated pyrimidines were synthesised by Heidelberg more than  fifty 
years  ago1,  and  fluorinated  Uracil  was  introduced  into  clinical  use  almost 
immediately.  
Using a definition that is often over-used in the last years to describe 
drug development, Fluorouracil can be considered one of the first “targeted” 
drugs2:  it  was  specifically  designed  in  order  to  interfere  with  a  precise 
molecular target. Inhibition of thymidylate synthase (TS) is probably the major 
mechanism of antiproliferative activity of Fluorouracil, representing an elegant 
example of targetting. 
The identification of novel targets for Fluorouracil activity (interference 
with  DNA  and  RNA  metabolism)  and  the  description  of  the  complex 
intracellular  biochemical  pharmacology  of  this  drug3,  led  to  attempts  to 
manipulate  the  different  metabolic  pathways  by  interfering  with  the 
concentration  of  intracellular  cofactors  required  for  the  separate  anabolic 
reactions. 
This attempt to influence how a cell would metabolise 5FU was defined 
as  “modulation”  4.  This  procedure  was  mostly  used  for  the  treatment  of 
colorectal cancer: as already stated for many years 5FU was the only drug with 
a consistent activity in this disease, and it was mandatory to exploit any mean 
of increasing its antitumour activity 5.
Several  agents  have  been  used  as  “modulators”  of  Fluorouracil:  this 
generally implied that the modulating agent would be devoid of antiproliferative 
activity, or at least due to the dose/schedule selected would contribute only to 
a limited extent to the cytotoxic effect observed. 
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List of the abbreviations used in the figures 
Molecules
5’DFCR 5’-deoxy-5-fluorocytidine
5’DFUR 5’-deoxy-5-fluorouridine 
5FU 5-fluorouracil
BAL beta-alanine
CDHP 5-chloro-2,4-dihydroxypyridine 
CH2-THF 5,10-methylene-tetrahydrofolate
CPT-11 irinotecan
dUDP deoxy-uridine-diphosphate
dUMP deoxy-uridine-monophosphate
dUTP deoxy-uridine-triphosphate
FA folinic acid (the same as leucovorin) 
FDHU fluoro-dihydrouracil 
FdUDP              5-fluoro-2’-deoxyuridine-5’-diphosphate
FdUMP             5-fluoro-2’-deoxyuridine-5’-monophosphate 
FdUTP 5-fluoro-2’-deoxyuridine-5’-triphosphate
FT ftorafur 
FUDP 5-fluoro-uridine-5’-diphosphate
FUMP 5-fluoro-uridine-5’-monophosphate
FUTP 5-fluoro-uridine-5’-triphosphate
FUPA α-fluoro-β-ureidopropionate 
LV leucovorin (5-formyl-tetrahydrofolate) (the same as folinic acid) 
MTX methotrexate
Oxo oxonic acid
PALA N-phosphonacetyl-l-aspartate 
S-1 a mixture of FT, Oxonic acid and CDHP (the molar ratio of 1:0.4:1)
THF tetrahydrofolate 
UDPG               uridine-diphospho-glucose
Urd uridine
UFT a mixture of Uracil and FT  (the molar ratio is 4:1) 
Enzymes
2A6 cytochrome P450 2A6 
CES carboxyl-esterase
DHFR dihydrofolate reductase
DPD dihydropyrimidine dehydrogenase
OPRT orotate-phosphoribosyl-transferase
RR ribonucleotide reductase
TK thymidine kinase
Topo-1  topoisomerase 1
TP thymidine phosphorylase
TS thymidylate synthase
UK uridine kinase
UP uridine phosphorylase 
7
Legend to figure 1: Metabolism of 5-Fluorouracil
The major activation pathways is catalysed by OPRT. An alternative pathway is catalysed by UP and UK. 
Direct conversion of 5FU via TP and TK is limited because of the lack of the co-substrate deoxyribose-1-
phosphate.
Activation to deoxynucletotide FdUDP is catalysed by RR. FdUDP is then converted to FdUMP, the inhibitor of 
TS. 
FUTP may also be incorporated into RNA and FdUTP into DNA. 
5FU can be degraded by DPD and this represents about 80% of its metabolism. 
It is also possible to administer oral prodrugs of 5FU: capecitabine (Xeloda) which has to be activated into 5FU 
by several enzymes, or Ftorafur which is a costituent of UFT and of S-1 and is activated by the cytochrome 
P450-2A6.
FUR
5FU
FUMP
FUdR
FUDP
FdUMP
FdUDP
dUMP
dTMP
dTDP
dTTPFUTP FdUTP
RNA DNA
5’DFUR
TS
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Many  modulating  agents  are  no  more  used  clinically  with  this  aim: 
Levamisole,  Interferon,  Hydroxyurea,  Cisplatin,  PALA  (N-phosphonacetyl-l-
Aspartate) 5.   
Special attention should be given to the role of methotrexate, even if this 
agent is at present uncommonly used as a modulating agent. In this case it 
was shown in a clinical experience not only that results improved, but also that 
the interval between drug administration had a key role  6. Furthermore this 
was the first agent that was reported in a meta-analysis to improve survival of 
patients with advanced colorectal cancer 7. 
The  most  widely  used  modulating  agent,  and  the  one  with  the  most 
convincing biochemical rationale, is folinic acid. The first evidence that this 
molecule, that is  by itself devoid of any antiproliferative effect, increased the 
activity of 5FU was obtained in vitro  8. The combination of Fluorouracil and 
folinic acid was rapidly introduced into clinical practice9, and was the subject 
of extensive phase III trials and of meta-analyses that evaluated whether there 
was a real benefit of the combination over Fluorouracil alone. Data consistently 
showed that in advanced colorectal cancer the response rate  was superior for 
modulated Fluorouracil  9 and that the toxicity profile was quite different with 
diarrhoea representing a relevant and sometimes serious problem. Survival, 
however, was only improved to a limited extent 10. 
It  should  be  mentioned  that  Fluorouracil  modulation  by  folinic  acid 
proved effective only when Fluorouracil was administered as a bolus injection. 
When a prolonged infusion was used, the association of folinic acid increases 
toxicity: this was demonstrated both in a pre-clinical model and in patients  11. 
Fluorouracil can be administered according to different schedules: this is 
based on sound pharmacological bases and it has become technically feasible 
thanks  to  the  development  of  infusion  devices  that  allow  the  continuous 
infusion  over  several  days  with  limited  discomfort  for  patients.  As  already 
mentioned for modulation, these different regimens have been most extensively 
evaluated in colorectal cancer, in an attempt to improve the limited efficacy of 
standard Fluorouracil administration. 
Bolus  injection,  that  should  last  only  2-4  minutes  in  order  to  avoid 
reducing antitumour activity  12, has been compared with prolonged infusions 
lasting  several  days  13.  Similarly  to  what  happened  for  modulation  with 
leucovorin, response rate increased, toxicity was different and mostly gastro-
intestinal, but in patients with advanced colorectal cancer overall survival did 
not differ 14. 
In an attempt to build on clinical experience, several studies have been 
conducted  on  treatment  schedules  that  combined  bolus  injection  and 
prolonged  infusion,  using  different  modulating  agents.  The  experience  by 
Sobrero et al., that combined methotrexate and bolus Fluorouracil as used by 
Marsh with continuous infusion, proved to be superior  to standard treatment 
in terms of response rate, but not in terms of survival 15. 
A similar combination, that has met with wide approval in Europe, is the 
combination  of  modulated  Fluorouracil  bolus  for  two  consecutive  days 
associated to a 48-hours infusion  16. This schedule is now commonly used, 
particularly in 
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Legend to figure 2: modulation of 5-Fluorouracil 
LV increases and prolongs the inhibition of TS by FdUMP by providing an excess of CH2-THF 
that stabilizes the ternary complex formed by TS-FdUMP-CH2-THF. 
MTX inhibits DHFR and results in an increase in TS inhibition. 
Uridine, and its  prodrug UDPG, compete with FUTP for incorporation into RNA but does not 
affect TS inhibition: it thus reduces the toxic side effects of 5FU but not its antitumour activity. 
CPT-11 (Irinotecan) inhibits Topoisomerase-1 and leads to DNA damage in addition to that caused 
by FdUTP. 
Oxaliplatin forms DNA adducts that result in additional DNA damage. 
5-FU FUMP
RNA
FdUMP
dUMP
CH2-THF
DHF
TS DNA
FUDP FUTP
FdUDP
uridine
FdUTP
dTMP
Oxaliplatin
CPT-11
Topo I
DNA 
damage
LV
THF
DHFRMTX
UDPG
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combination with other anticancer agents, namely Irinotecan (FOLFIRI) 17  or 
Oxaliplatin (FOLFOX) 18 or both (FOLFOXIRI) 19 and with biologicals  20, 21.  
The prolonged infusion of 5FU is also commonly used in combination 
with radiotherapy in the treatment of locally advanced rectal cancer and of 
other tumours (oesophagus, head-and-neck, anal squamous carcinoma). 
Prolonged infusion can also be obtained by the oral administration of 
precursors of Fluorouracil  22: in some cases this “prodrug” is associated with 
an inhibitor of the main degrading enzyme for Fluorouracil: DPD 23  ,24  . 
The  chapters  of  the  present  thesis  mostly  deal  with  Fluorouracil 
modulation obtained with folinic  acid and with studies on the possibility  of 
increasing  Fluorouracil  dose  by  reducing  its  toxic  side  effects  with  Uridine 
derivatives.  We  also  performed  a  pharmacokinetic  analysis  of  high-dose 
Fluorouracil, trying to identify a limited sample strategy that may provide a 
simple method to predict drug exposure and therefore antitumour activity and 
toxicity.
Chapter 2 is a general review on the modulation of 5FU using different 
compounds: as already mentioned, many of these are today almost abandoned 
and folinic acid is the only that is widely used. In this chapter Cisplatin is 
mentioned  as  a  “modulating  agent”  of  5FU:  this  is  a  point  that  is  not 
considered of any interest today, even if the combination of 5FU and cisplatin 
is commonly used in the treatment of several tumour types such as head-and-
neck and gastric cancer. In fact Oxaliplatin, a more recent platinum derivative 
that is commonly associated with 5FU in the treatment of colorectal cancer, 
has never been proposed as a modulating agent and the interaction between 
the two drugs is rather considered a typical example of synergism. 
In  chapters  3  and  4  we  describe  results  obtained  in  mice  using  a 
prolonged  administration  of  5FU:  results  are  similar  to  those  obtained  in 
patients, and this shows how a properly used preclinical model may help in the 
development of anticancer treatment. The antitumour activity, haematological 
and  gastrointestinal  toxicity,  and  the  comparison  with  bolus  treatment  all 
reproduce aspects commonly seen in clinical practice.  
The relationship between 5FU dose and its pharmacology is described in 
chapter 5.  We analysed data obtained from patients treated with increasing 
doses thanks to Uridine rescue and we report a relationship between AUC and 
toxicity. We also describe the use of a limited sampling strategy in order to 
predict AUC. 
Chapter 6 describes the pharmacology of  Uridine.  This  is  particularly 
relevant  since  5FU  was  synthesised  in  order  to  interfere  with  Uridine 
metabolism.  Furthermore  Uridine,  or  precursor  molecules,  can  be  used  to 
reduce 5FU toxicity. This  is described in chapter 7 for in vitro studies and 
chapters 8 and 9 where we discuss results obtained in mice that show how 
using a proper schedule of administration it is possible to reduce 5FU toxicity, 
to administer a higher dose and to obtain better antitumour activity. We also 
investigated the molecular mechanisms involved in Uridine rescue, and found 
a reduced incorporation of 5FU derivatives into RNA while TS inhibition was 
not affected. 
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Fluorouracil is being used since 50 years, and its role in the treatment of 
many tumour types remains pivotal. New drugs are being combined with it, but 
it has never been completely replaced. Several aspects of its pharmacology are 
not yet fully described, especially in combination with new drugs; 5FU has also 
been described to interfere with signalling pathways,  and there probably is still 
room to improve clinical results. 
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Chapter   2
  
5-Fluorouracil modulation in the 
chemotherapy of colorectal cancer.
Giovanni Codacci-Pisanelli and Fabrizio Franchi.
Adapted from: The Italian Journal of Gastroenterology 
1994 Sep; 26 (7): 369-376 
Summary
More than ten years after the introduction into the clinic of Folinic 
Acid associated with 5-FU in the treatment of colorectal cancer, it appears 
that in terms of objective responses, associations with modulating agents 
are more effective than 5-FU alone. An improvement in survival has been 
observed only in some studies, but this remains a debated subject. These 
results can probably be further improved by multiple modulation using also 
Interferon and by a more careful evaluation of drug scheduling. The data on 
the  activity  of  Levamisole  and  5-FU  in  the  adjuvant  treatment  of  colon 
cancer  await  the  publication  of  confirmatory  trials  and  do  not  show  a 
correspondence in the therapy of advanced carcinoma.
The comparison of reports from different groups emphasises the need 
of protocol standardisation and of a better description of patients based not 
only on the pathological staging, but also on the biological characteristics of 
the tumour.
Key Words: 5-Fluorouracil,  Colorectal Cancer, Folinic Acid, Modulation.
Running title: 5-FU modulation in Colorectal Cancer
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Colorectal carcinoma (CRC) is one of the main causes of cancer death 
in  the  western  world  [1],  and  its  treatment  remains  one  of  the  most 
disappointing  features  of  oncology.  Surgery  alone is  curative  only  in the 
initial stages, while the majority of patients requires treatment for advanced 
tumour, either at presentation or at relapse.  Results in the treatment of 
widespread disease, however, are far from satisfactory. 5-Fluorouracil (5-FU) 
has long been considered the treatment of choice of advanced CRC even if 
the response rate (RR) in the advanced disease is around 20 % [2-3]. 
Various attempts have been made to improve  the RR using higher 
doses  or  by  designing  new  schedules  of  5-FU  administration,  but  no 
significant improvements have been reported for the different regimens [4-5]. 
Interesting RR have been obtained with continuous infusion,  particularly 
when  dose-intense  schedules  were  used  [6],  but  this  was  hampered  by 
serious toxicity  while  the  duration of  responses  and of  survival  was not 
better than with standard bolus treatment [7].
The combination of  5-FU with other antineoplastic  drugs has been 
widely  tested,  but  results  have  generally  been  disappointing  [8].  In 
particular  the  association  with  Nitrosoureas  or  with  Mitomycin  C,  that 
seemed promising in initial studies [3, 9, 10] did not show a significantly 
higher RR in later trials [11-12].
In recent years the attention has been focused on the possibility of 
modulating  the  action  of  5-FU  using  compounds  that  influence  its 
pharmacokinetics, the intracellular metabolism or the mechanism of action. 
The most  extensively investigated agents in advanced disease are Folinic 
Acid (FA) and Interferon (Ifn). A modulating activity has also been proposed 
for  some  cytotoxic  compounds:  Methotrexate  (Mtx),  N-(phosphonacetyl)-l-
Aspartate  (PALA),  Cisplatin  (CDDP) and Hydroxyurea (HU),  but in these 
cases it is necessary to distinguish the additive antitumour activity from the 
actual modulating effect on 5-FU. 
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Levamisole (Lev) will be discussed in this paper even if its interaction 
with 5-FU is probably different from a pure biochemical modulation. 
We  will  focus  on  the  clinical  aspects  of  5-FU  modulation  in  the 
treatment  of  CRC.  The  biochemical  mechanisms  have  already  been 
extensively described [13] and will only be shortly reported where necessary. 
FOLINIC ACID   
The  clinical research on the modulating activity of FA followed the 
results of in vitro studies demonstrating that folates are required cofactors 
in the inhibition of Thymidylate Synthase by FdUMP [14]. This association 
has been widely employed in clinical practice after the publication of the 
work  of  Machover  [15]   that  obtained  a  RR  of  56  %  in  non-pretreated 
advanced  CRC patients.  These  data  are  consistent  with  the  encouraging 
results seen in gastric [16]  and breast cancer [17] . 
The  work  of  Machover  has  arisen  a  lively  debate:  some  authors 
reported similar or even higher RR, others obtained more limited success, 
and some groups denied that FA can actually increase the activity of a full 
dose of 5-FU, both in the animal [18]  and in the clinic [19].
It  has  been suggested that  FA administration could  also  induce  a 
response to 5-FU in tumours that were resistant to this drug due to an 
insufficient intracellular folate pool.  Despite some positive clinical  reports 
[15,  20,  21],  however,  it  appears  that  meaningful  responses  are  not  a 
frequent occurrence in resistant tumours [22]. 
The direct comparison of 5-FU alone versus the association 5FU-FA 
has been performed by several groups, and data from randomised studies 
are reported in the table.  It  was soon evident that  the administration of 
equal doses of 5-FU in the two arms was incorrect since the combination 
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showed a higher toxicity. The comparison of equitoxic doses, on the other 
hand, has proved a difficult task since the toxic effects are different. In these 
conditions the dose-intensity actually delivered to the patients is often not 
homogeneous, and this may explain some of the differences in the results 
obtained [23].
Response  rates are generally  better  with the  combination:  in some 
cases,  when  tested  in  controlled  trials,  the  advantage  for  5FU-FA  is 
statistically significant (see table), but it appears that this may be due to the 
unusually low RR obtained with 5-FU alone rather than to a really higher 
efficacy of the association [24]. 
The comparison of results of different groups is often misleading since 
5-FU and FA have been administered according to different schedules. Low 
and high doses of FA, however, have been compared in randomised trials 
and the data suggest that there may be no difference in the activity [25]  so 
that a low dose has been used in several studies [26-29]. It should in fact be 
considered that FA increases the cost  of  treatment, especially when high 
(200 mg/m2) or very high doses (500 mg/m2) are employed. The influence of 
the time interval between FA and 5-FU has not been sufficiently analysed in 
the clinic, while studies in the animal suggest that this may be a crucial 
element [30]. The lack of conclusive data on this subject is also due to the 
incomplete knowledge of the influence of the intracellular anabolism of FA 
on its modulating activity.
A  crucial  point  in  the  evaluation  of  the  efficacy  of  5FU-FA  is  the 
improvement in survival: in some cases a significantly positive result has 
been obtained [29, 31], in other studies the survival advantage was lost with 
longer follow-up [32]. Some of the trials are biased on this aspect by the 
possibility of a cross-over between the arms  [19, 33]. 
It is important to note that the comparison of responding and non-
responding patients may be influenced by the increased survival of those 
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that obtain a stabilisation of disease but are not considered as responders 
[8]. A significantly prolonged survival for patients with Stable Disease (SD) 
over Non Responders (NR) has been described in some studies  [7, 34], and a 
remarkable difference between the duration of response and survival has 
also been observed [35]. Finally, it should be mentioned that many studies 
have  been  published  after  a  rather  short  median  follow-up,  making  the 
evaluation of long-term results impossible.
The  results  obtained  by  the  association  of  5-FU with  FA  must  be 
considered together with the toxic effects of  treatment. These are heavily 
conditioned by the doses and by the scheduling of the two drugs. Bolus 
administration  mostly  results  in  myelosuppression,  while  continuous 
infusions  mainly  cause  mucosal  toxicities.  Fatal  complications  have  also 
been observed [36, 37]: these are generally the effect of profuse diarrhoea 
associated  with  myelosuppression,  a  threatening  situation  especially  in 
patients with impaired performance status. A better understanding of the 
problem and the development of antidotes to the toxic effects are making 
this  treatment  more  acceptable  and  less  dangerous  [38].  Patients  also 
benefit from the use of analytical techniques that permit a more accurate 
dosing of drugs on following cycles in order to prevent serious side effects [7] 
and to ascertain that effective plasma concentrations are attained [39]. This 
is particularly important when drugs are administered orally and/or in low 
doses, as it is the case with FA in some protocols [31, 32].
The  possibility  of  modulating  5-FU  continuous  infusion  [41]  or 
locoregional  chemotherapy  is  now  being  studied.  In  preclinical  models 
toxicity  has  often  been  severe,  but  results  with  lower  drug  doses  were 
interesting.
The efficacy of 5FU-FA is also being tested as an adjuvant to surgery. 
In this setting it will be possible to reduce the influence of tumour burden 
heterogeneity of patients with advanced disease and the induction of disease 
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stabilisation will no more affect the evaluation of treatment efficacy.
METHOTREXATE   
MTX shows an interesting synergism with 5-FU, and this combination 
is active in the treatment of other solid tumours. In CRC the response rate is 
over 30 % [42, 43], and significantly prolonged survival versus 5-FU alone 
has been demonstrated by the Nordic GIASG [44]. 
The attention of clinicians is now focused on the doses and schedule 
to be employed. The importance of the interval between 5-FU and MTX has 
been first observed in vitro [45] and later in a clinical trial [31]. In this study 
the comparison of  two 5FU-MTX associations showed that a low dose of 
MTX 24 hours before 5-FU gave better results than a higher MTX dose with 
a shorter interval: the RR improved even if the dose intensity was reduced. 
These observations have recently been validated in a randomised trial [46]. 
The comparison of two identical associations of MTX and 5-FU, given with a 
short (1 hour) or long (24 hours) interval showed that a longer period made 
the combination more effective. It cannot be excluded that in the schedule 
with  the  longer  interval  5-FU was also  potentiated  by  the  contemporary 
administration of Leucovorin, given in this protocol as a rescue for MTX, but 
the importance of this element seems limited [47-49].  The efficacy of low 
doses  of  MTX  associated  with  5-FU  is  particularly  important  since  the 
toxicities  of  the  two  drugs  are  similar,  and  serious  complications  are 
frequent when higher doses are employed  [7].
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INTERFERON
The association of  5-FU with Ifn  has  been used in several  clinical 
studies and it has been extensively analysed in vitro. The synergism of the 
two drugs has not yet received a satisfactory biochemical explanation: some 
authors  suggest  that  the  effect  is  due  to  an  alteration  in  5-FU 
pharmacokinetics [50], but in vitro data indicate that interference with gene 
expression may play a central role [51]. This combination has given good 
results  in  CRC,  especially  in  patients  who  had  not  received  any 
chemotherapy  [52].  As  in  most  instances,  however,  the  initial  excellent 
results  were  not  confirmed in later  trials  [53-54].  In studies on multiple 
modulation, Ifn has also been shown to improve the efficacy of 5FU-FA, and 
several  randomised  studies  are  in  progress  to  evaluate  the  actual 
contribution of Ifn to this combination [55]. 
LEVAMISOLE   
The medical treatment of CRC has changed after the publication of 
reports  on the effect  of  the association of  5-FU and Lev in the adjuvant 
treatment of colon cancer [56-57]. Based on these data a NIH Consensus 
Conference stated that in colon cancer "the fluorouracil-levamisole regimen 
is the standard with which new therapies should be compared" [58]. 
This statements is difficult to accept since it is based on two studies 
that lack a control arm with 5-FU alone. It is important to point out how 
such a position also raises some serious biases in the design of  clinical 
trials. It appears that the use of a control arm treated with 5-FU only would 
be unethical while this is the only way to determine the real value of the 
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5FU-Lev association. Until the results of comparative trials are published it 
is questionable that the NIH recommendation can be accepted as a definitive 
assertion.
OTHERS
Among less commonly used modulating agents PALA has not  been 
extensively  used  in  clinical  practice  even  if  results  were  encouraging.  A 
recent clinical study reported a RR of 43 % in CRC  [35]. The limited results 
obtained in previous trials were probably due to the relatively high dose of 
PALA  and  to  the  schedule  chosen  [59-60]  that  did  not  allow  the 
administration of 5FU at its full dose. The importance of this element has 
been demonstrated in a clinical study in which, using a constant amount of 
PALA, the RR increased with the dose of 5FU delivered to patients [61].
Clinical results with the association of 5-FU and HU were not better 
than 5-FU alone [12][62]  despite  the promising activity  observed in vitro 
[63]. Recent data suggest that HU may be useful in multiple modulation of 
5-FU. 
The association of CDDP and 5-FU for the treatment of CRC has not 
proved as active as it is in other solid tumours [64-65]. In some reports it  
was  found  to  be  more  effective  than  5-FU  alone  [66],  but  questionable 
results have been obtained by other groups [31, 67, 68]. Scheduling may 
prove an essential element to obtain the best results with this combination.
Multiple modulating agents are now being employed by many groups. 
The addition of Ifn to 5FU-FA in CRC has already been studied [69-75] and 
results seem promising. This is in agreement with what was expected [76], 
and randomised trials to assess the actual role of Ifn in this association 
have been started [55].  CDDP, FA and HU have been associated to 5-FU 
[77] and a study evaluating 5FU-FA with or without HU has been published 
23
[78]. Further studies are necessary to identify the schedule that will give the 
best results when using these multidrug combinations [38]. 
The conflicting results that have been obtained by chemotherapy in 
advanced CRC might in part be explained by the heterogeneity in series of 
patients that are similar according to clinical and pathological criteria [66].
Concerning  pathological  staging  it  is  necessary  to  divide  results 
obtained in colon and in rectal cancer, that are often reported together, and 
it would be useful to stratify patients also according to the tumour mass 
[79]
Recent findings have shown that molecular and cellular features are 
often  precisely  related  to  the  clinical  behaviour  of  the  tumour.  Flow 
cytometric  analysis  of  DNA  content  is  perhaps  the  most  widely  used 
biological marker. A recent consensus conference however concluded that 
ploidy  by  itself  does  not  provide   additional  significant  prognostic 
information in CRC.  Other parameters, such as cell kinetics and markers of 
infiltrating  activity  (laminin  receptors),  are  of  great  interest  in  predicting 
both prognosis and response to chemotherapy [80]. Gene products (cmyc, 
bcl-2 and p53) are regarded with great attention as putative indicators of 
biological aggressiveness or of resistance to anticancer drugs. 
In conclusion, despite the conflicting reports in the literature [81], it 
can generally be assumed that in terms of RR  [46-47] 5-FU modulation is 
more effective than 5-FU alone in the treatment of advanced CRC  [82-84]. 
Even if some enthusiastic reports have been published in the past years 
with different approaches,  the RR is now converging toward a more widely 
accepted 35 %  [25, 28, 38, 85]. Prolonged survival has also been reported 
by some groups  [29, 31, 86], but this remains a debated point.
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The  objective  of  research  should  now  be  to  identify  a  therapeutic 
option to be used in general practice and not only in clinical trials. A wide 
agreement  on several  elements,  such as drug doses  and scheduling,  the 
criteria for patient selection and a more precise stratification of cases. The 
accurate design of new clinical trials will reduce the time required to give a 
definite answer to these questions. 
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Introduction
Clinical interest in pyrimidines derives from the study of related metabolic 
disorders and from the increasingly recognised role played by these molecules in 
sugar  and lipid  metabolism.  Furthermore  the  enzymes involved  in  pyrimidine 
metabolism  are  not  only  important  targets  for  antiproliferative  and 
immunosuppressive  drugs  (1),  but  a  role  for  thymidine  phosphorylase  has 
recently been identified in an apparently unrelated field (angiogenesis) (2).
The  widespread  consequences  produced  by  disturbances  of  pyrimidine 
metabolism  and  particularly  of  their  de  novo synthesis  (3)  underscore  the 
importance  of  maintaining  plasma  levels  within  a  narrow  range.  This  is 
particularly important for Uridine (Urd), since this molecule not only plays a key 
role in pyrimidine biosynthesis, but also has specific biological effects (4). In the 
table we list some of the published data concerning Urd concentration in different 
tissues; further informations can be obtained from other reviews (5, 6). 
Despite  extensive  research,  the  mechanisms  that  control  Urd  plasma 
concentration  are  not  entirely  clear.  Several  detailed  reviews  on  pyrimidine 
metabolism have been published in the past (7-9), focusing on the general aspects 
of pyrimidine metabolism,  while  more recent  reviews concentrated on several 
enzymes (e.g. 10-13) although some aspects of Urd were also reviewed (14). In 
this paper we try to summarize the available knowledge on Urd sources and will 
also  briefly  discuss  the  relevance  of  pyrimidines  in  anticancer  therapies  and 
finally the indications for the administration of pharmacological doses of Urd in 
specific clinical settings. 
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Legend to the figure
Schematic representation of Uridine metabolism. 
Uridine derived from de novo  or salvage pathways can be phosphorylated to 
UMP, released in plasma or it can be degraded to Uracil and to further 
breakdown products. The relative importance of the different routes depends on 
the cell type and on the metabolic status of the cells and of the organism. Orotic 
acid has been indicated separately since it represents a useful experimental tool 
for the evaluation of the de novo synthesis. Uridine is actively taken up by cells 
from plasma by either facilitated diffusion or by Na+ dependent concentrative 
mechanisms (1), but passive diffusion (2) becomes prevalent when its 
concentration is >20 μM. 
Some inhibitors of metabolic processes have been marked: PALA and Brequinar 
Sodium block the de novo  synthesis of Uridine, CPE-U inhibits Uridine kinase, 
BAU inhibits the phosphorylase, ethynyl-uracil (EU) blocks the further 
degradation of Uracil by dihydropyrimidine dehydrogenase (DPD). Some of 
these antimetabolites modulate the activity of 5FU.
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Sources of plasma Uridine
Clinical and experimental evidence suggests that the liver plays a major 
role in maintaining plasma Urd concentration within a relatively fixed range. This 
role implies the ability to synthesize pyrimidines, both through the de novo and 
the  salvage  pathways,  and  the  capacity  of  degrading  Urd  when  its  plasma 
concentration exceeds the physiological range. In the figure we give a simplified 
model of Urd metabolism and of how some antimetabolites may interfere with 
pyrimidine metabolism, in the salvage of nucleosides derived from exogenous 
sources  or  from the  degradation  of  nucleic  acids,  in  the  de  novo and  in  the 
catabolic pathways. 
The importance of  de novo pyrimidine production was indicated by the 
early observation that the diet is not a significant source of nucleotides (9) and by 
the pathological consequences of disorders of this pathway resulting in hereditary 
orotic  aciduria  (HOA)  (reviewed  in  (3)).  Deficiency  of  pyrimidine  5'-
nucleotidase, which can also provide Urd by the degradation of nucleotides is 
associated with haemolytic anaemia (15). Lead poisoning can also cause a defect 
in this enzyme (16). 
The  excretion  of  Urd  in  plasma  by  the  liver  has  also  been  shown  in 
experiments in the isolated organ (17). This phenomenon is in agreement with the 
similar role played by the liver as a source of purines for different tissues. Several 
experiments  have been performed in rats  in order to determine how the liver 
regulates Urd concentration in plasma. It appears that, in this species at least, the 
liver  is  very  effective,  but  its  action  does  not  seem to  be  economical.  The 
available data suggest that the liver degrades all the Urd arriving from the portal 
system, and that the Urd in the systemic circulation is formed de novo by the liver 
itself. Preformed  Urd is only  found in  the systemic circulation when its 
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Uridine concentrations in plasma and in tissues from various species.
Species Tissue Uridine (μM) Reference
Man plasma 3.32±0.58 (27)
bone marrow 10.44±5.06 (27)
plasma 2.8-7.8 (30)
Rat plasma 1.4±0.6 (25)
Mouse plasma 8.9±1.2 (37)
plasma 9.7±1.3 (39)
plasma (peak) (4) 10 (36)
plasma (nadir) (4) 5 (36)
plasma 3.2±1 (1) (33)
Mouse (C57Bl) liver 229±57 (3) (23)
liver 27.1±4.8 (1) (33)
kidney 31.2±4 (1) (33)
spleen 38±4.7 (1) (33)
intestine 12.6±2.3 (1) (33)
Mouse tumours Colon 26 10±2 (2) (34)
Colon 38 97.6±10.9 (23)
Colon 38 110±13 (2) (34)
Colon 38 7.3±1.1 (1) (33)
(1) nmol/g
(2) nmol/g wet weight
(3) pmol/ mg wet weight
(4) Peak concentration was found at 2 HALO, nadir concentration at 14 HALO.
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concentration in the portal system exceeds 50 μM and the uptake capacity of the 
liver is saturated (17). The catabolic and secretory activities of the rat liver on Urd 
appear to be independent (18). In mice and in humans, however, the salvage of 
Urd is probably different (19), and in these species the liver seems to use Urd 
more efficiently than in rats (20,21).  Another source of Urd in tissues  and in 
plasma  may be  represented  by  the  deamination  of  cytidine  to  Urd.  Cytidine 
proved to be a more effective precursor for nucleotide synthesis than Urd (22-24). 
Regulation of plasma Urd concentration  
The liver is able to act directly on Urd in plasma: in experiments on the 
isolated rat liver it was shown that this organ maintained a constant concentration 
of Urd in the perfusate by reducing the output when the fluid was recirculated 
(25). The effective activity of the liver explains the clinical evidence that tracer 
and pharmacological doses of Urd rapidly disappear from plasma, in contrast to 
cytidine (24,26-28). In some studies in patients Urd catabolites have not been 
characterised (27), but this may be a detection problem since in this study the 
dose of Urd was very low. These results give an indication concerning the first 
step in catabolism, the transformation of Urd into Uracil, but do not allow an 
evaluation of further degradation of the pyrimidine bases. 
In mice oral Urd increased the plasma levels only after the administration 
of large doses (3500 mg/kg), with a bioavailability of 7% when compared with 
subcutaneous injection. The area under the concentration vs time curve showed a 
non-linear increase with dose, suggesting that hepatic clearance capacity must be 
saturated before detectable amounts of oral Urd pass into the systemic circulation 
(29). Studies in humans showed that  the bioavailability of oral Urd is similar 
(~10%), but a dose of 5 g/m2 was sufficient to increase plasma Urd concentration 
to ~50 μM (30), while in mice doses of a similar magnitude were not effective. 
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An indirect evidence that oral administration of Urd in humans is more effective 
than in rodents comes from data obtained during treatment of patients with HOA. 
Even if pharmacokinetic data are not available, it is clear from clinical results that 
oral doses as low as 50 mg/kg/day can be sufficient to correct the consequences 
of this disorders (3). 
It has been suggested that in humans there may be multiple sites of uptake 
and  degradation  of  Urd  (27)  while  in  the  rat  the  liver  represents  the  main 
catabolic site. Pyrimidine nucleoside phosphorylases from different sources have 
been characterised: concerning Urd-phosphorylase it appears that this enzyme is 
highly specific for Urd in human liver, but not in mouse liver, while an opposite 
pattern can be observed for thymidine phosphorylase. Interestingly the enzymes 
extracted from human placenta are more similar to those of murine liver than to 
those of human liver (31). 
The primary role of the enzymes that degrade Urd in regulating the plasma 
concentration of pyrimidines can be deduced by the ability of inhibitors of Urd 
phosphorylase (benzylacyclouridine, BAU) to increase the plasma concentration 
of Urd and to prolong the half-life of exogenous Urd (18,32). It has also been 
shown that in mice the size of Urd pools in different tissues largely depends on 
the activity of the phosphorylase. In a series of experiments the intestine showed 
the highest  phosphorylase activity and the lowest  Urd content,  the spleen had 
opposite  values while liver  and kidney were intermediate.  It  is  of interest  for 
studies  on experimental  cancer treatment  with antimetabolites  that  the murine 
tumour  Colon  38  had  a  high  phosphorylase  activity  and  a  very  low  Urd 
concentration (33). However in another Colon 38 model low Urd phosphorylase 
activity  and  higher  Urd levels  were  observed,  whereas  Colon  26  had  a  high 
phosphorylase  activity  and  low  Urd  levels  (see  table)  (23,34).  Recently  we 
demonstrated  that  murine  colon  tumours  coming  from  the  same  source  but 
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propagated in different laboratories become very different concerning metabolic 
properties and response to anticancer agents (35).
The  evidence  that  Urd-phosphorylase  has  a  circadian  rhythm  that  is 
opposite  to the rhythm in plasma Urd concentrations (36) indicate  a potential 
involvement of Urd in the regulation of physiological functions that also show a 
circadian  variation,  possibly including  the  sleep/wake cycle.  Urd peak in  this 
study was observed at 2 hours after light onset (HALO) while nadir values were 
seen at 14 HALO.
The observation that  de novo synthesis  of Urd does not  have the same 
importance in maintaining a constant  Urd plasma concentration in the various 
species might explain the conflicting results obtained with inhibitors of the  de 
novo pathway. Brequinar sodium decreased the plasma levels of Urd in mice and 
in patients, even if in different proportions (37,38), while N-phosphonacetyl-l-
aspartate  (PALA) had a similar  activity  in  mice (39)  but  a limited  impact  in 
patients (40) and no effect in rats (41). Brequinar, on the other hand, had no effect 
on the Urd pools of the mouse liver, consistent with the presence in this species of 
a significant activity of the salvage pathway. The inhibition of the pyrimidine de 
novo pathway  was  associated  with  a  significant  lymphocytopenia  in  cancer 
patients  (38),  and  Brequinar  is  currently  being  evaluated  for  its  possible 
applications  as  an  immunosuppressive  agent  in  transplantation  (42).  Another 
application  of  inhibitors  of  de  novo pyrimidine  synthesis,  specifically  the 
dihydro-orotase  and  the  dihydro-orotate  dehydrogenase  is  in  the  treatment  of 
parasitic disease (43): malarial parasites for example are largely dependent on de 
novo synthesis of pyrimidines since they lack salvage enzymes. 
Together these studies clearly indicate an important role of the  de novo 
pathway in maintaining sufficient plasma and tissue Urd concentrations.
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Salvage  
A concentrative pumping mechanism for the uptake of Urd from plasma 
has been described and characterised in several tissues (44-46), and the role of the 
phosphorylase in maintaining these pools has already been mentioned. 
The enzymes of the de novo synthesis of pyrimidines have been found in 
different  cellular  types,  but  many tissues  appear to depend largely on salvage 
synthesis  (8). The brain is probably the principal  example of this dependence 
(47,48), and several experiments in animals indicate that it requires the liver as a 
source  of  circulating  pyrimidines  (9).  Using  labelled  precursors  it  has  been 
possible to determine the relative importance of de novo and salvage synthesis in 
different tissues and in tumours of mice: de novo synthesis was prevalent in the 
intestine and, to a larger extent, in tumours, while the kidney preferentially used 
the salvage pathway. The two sources were used in roughly equivalent amounts 
in the liver (49). Unfortunately the brain was not included in this analysis, but 
data indicating the preference for the salvage pathway had already been published 
(50).
Bone marrow also depends on Urd salvage, much in the same way as it 
depends on the purines supplied by the liver. The peculiarity in this case is the 
presence in the bone marrow of a large amount of nucleotides that are released, 
for example, during the extrusion of reticulocyte nuclei and that may represent an 
additional  source  for  nucleotide  synthesis.  As  already  mentioned  indirect 
evidence  of  the  importance  of  pyrimidine  nucleotidase  also  comes  from the 
development of haemolytic anaemia in cases of enzyme deficiency. 
The importance of salvage for lymphocytes is suggested by the observation 
that  salvage  enzymes  have  a  low  activity  in  resting  conditions  (51,  52)  but 
increase  after  stimulation  with  PHA;  although  Urd  phosphorylase  is  also 
increased (53), this mitogenic stimulation is accompanied by an increase of Urd 
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incorporation  into  RNA.  Several  de  novo enzymes  are  increased  (Carbamyl-
phosphate  synthetase,  Aspartate  transcarbamylase)  but  some  are  not  (orotate-
phosphorybosyltransferase,  dihydroorotase)  (52-54):  however  the  rate  of 
synthesis  is  upregulated  due  to  an  increase  of  phosphorybosyl-pyrophosphate 
(51) which is accompanied by an increase in bicarbonate incorporation (54). 
 The ability of cells to adapt to the presence of sufficient Urd concentrations 
in the medium may depend on the inhibitory activity of UTP on CPS (52,55). It 
has been observed in vitro that leukaemic and hepatoma cells show a reduction in 
de novo pyrimidine synthesis that is proportional to the concentration of Urd in 
the medium (56,57). At concentrations similar to those found in plasma, de novo 
synthesis is reduced by >90% (56). Salvage synthesis was much less sensitive to 
regulation,  and even if  de novo synthesis  was switched off,  cellular  pools  of 
Uracil nucleotides continued to expand when exogenous Urd was present (56). 
The importance  of  exogenous  Urd as a source of  pyrimidines,  and the 
efficacy of the salvage pathway in humans, is exemplified by the treatment of 
HOA:  in  this  situation  it  is  possible  to  compensate  the  consequences  of  the 
defective de novo synthesis of pyrimidines by the administration of relatively low 
doses of oral Urd (while uracil, for example, is not effective) (3).
The role of salvage pathway and its influence on the activity of inhibitors 
of  de novo Urd synthesis has been clearly recognised (58): an effective salvage 
activity  may bypass  the  antiproliferative  effects  of  the  inhibition  of  de  novo 
synthesis.  The  recent  availability  of  a  specific  inhibitor  of  Urd-kinase, 
Cyclopentenyl-uracil (CPE-U) has also enabled to study in mice how the salvage 
pathway may reduce  the  effects  of  inhibitors  of  the  de  novo synthesis.  This 
compound was not toxic by itself, and it did not affect the growth of the animals. 
By preventing the use of Urd taken up from plasma, however,  it  was able to 
modulate the activity of inhibitors of  de novo pyrimidine synthesis. A dose of 
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PALA of 200 mg/kg/day for 5 days did not affect the growth of CDF1 mice, but 
when this schedule was combined with CPE-U it proved rapidly lethal (19). 
Together  these  findings  indicate  that  both  the  de  novo and  salvage 
pathways play a  role  in  the  synthesis  of  pyrimidine  nucleotides.  The relative 
importance of each depends on the tissue and on its proliferative status.
Compartmentation  
The  presence  of  different  sources  for  pyrimidines  suggests  that  these 
molecules may be separated into different compartments according to their final 
destination (5,59). Compartmentation is not always due to physical obstacles, but 
to the channelling of molecules through multienzymatic complexes or to the close 
proximity  of  different  enzymes.  Intracellular  structures  such  as  the  nuclear 
membrane, on the other hand, would hardly be effective due to the presence of 
wide pores (6,60). 
This subject has been studied by providing labelled precursors of de novo 
or salvage pathways of pyrimidines. Results  obtained from  in vivo or  ex vivo 
studies suggest that pyrimidines formed by the different pathways are used for 
specific purposes: salvaged Urd is used for the synthesis of nucleic acids, while 
molecules  formed  de novo remain  in  the cytoplasm to  be used for  metabolic 
intermediates  (sugars,  lipids,  etc.).  (22,61,62).  Similar  data  on  an  even  more 
specific distinction for pools of deoxycytidine nucleotides deriving from salvage 
or de novo synthesis have recently been published by others (63). 
It should be mentioned however that the subject of compartmentation is 
very difficult to study due to the development of a rapid equilibrium between the 
different pools, although this equilibrium is not reached at the same speed in the 
different  cell  types  (59).  These  technical  problems  may  explain  why 
compartmentation is not universally accepted (6) and remains a matter for debate. 
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Uridine administration
The administration of Urd has been mostly used in two conditions: in the 
treatment of HOA, that has already been mentioned, and in rescuing from the 
toxicity of fluoropyrimidines. 
In HOA Urd is generally administered orally at doses of 2-4 grams/day 
since lower doses, even if sometimes sufficient, have a more erratic effect. This 
dose is generally well tolerated and corrects the metabolic imbalance typical of 
this disease, but treatment must be continued indefinitely.
The  use  of  Urd  to  rescue  from  fluoropyrimidine  toxicity,  mainly  5-
fluorouracil (5FU), is a strategy that allows the administration of higher doses of 
the  anticancer  drug  (64,65).  Its  utility  has  been  shown  in  preclinical  and  in 
clinical experiments. The doses of Urd are much larger than those employed in 
HOA, and a plasma concentration  of  50-100  μM must  be maintained over  a 
prolonged time (two or three days) to obtain an effective rescue. Experiments in 
mice  gave  encouraging  results,  but  the  clinical  application  has  raised  some 
difficulties. The parenteral administration as a bolus, in fact, only resulted in a 
transient elevation of Urd concentrations in plasma (66). In contrast to what was 
observed  with  bolus  injections,  prolonged  infusions  were  complicated  by the 
appearance of phlebitis and of fever (67). 
The effect of Urd on body temperature has been studied in detail. In mice 
and rats high doses Urd cause a decrease in body temperature, while in humans 
and in rabbits fever is the main toxic  effect  (23,28).  These effects  have been 
attributed to an interaction of a degradation product with thermoregulation since 
the administration of the breakdown products also influenced body temperature. 
Inhibition of Urd phosphorylase by BAU, furthermore, partially prevented these 
effects (23,28).
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It has recently been shown that it is also possible to increase the pyrimidine 
pools in tissues by increasing the dietary intake of nitrogen, and thus the toxicity 
of fluoropyrimidines  may be reduced (68). This looks as a promising field of 
research,  but  it  is  necessary  to  exclude  any  confounding  effect  due  to  the 
interference with the nutritional status of the animal.
Due to the complications of the administration of Urd itself, several other 
strategies are currently being investigated, such as the combination of Urd with 
BAU (32). Also other precursors of Urd such as UDPG (69,70), however, are able 
to  exert  similar  protective  effects  against  myelotoxicity  and  gastrointestinal 
toxicity of 5FU (71). Interestingly Urd in combination with BAU is also able to 
protect against the toxic side effects of azidothymidine, that is used for AIDS 
treatment (72,73). Thus, both for the possibilities in the treatment of tumours and 
of AIDS there is much interest in the development of specific inhibitors of Urd 
phosphorylase (11) which may enable to regulate Urd plasma and tissue pools 
without  undesired  side  effects  such  as  disturbances  of  body  temperature 
regulation.
Conclusions
The  interest  in  pyrimidines,  and  in  Urd  metabolism  in  particular,  is 
increasing: the metabolic pathways that lead to the synthesis of these molecules 
are  important  targets  in  anticancer  and  antiviral  treatment.  The  plasma 
concentration  of  Urd,  in  this  case,  can  often  determine  the  response  or  the 
resistance to treatment or the toxicity of treatment. The development of specific 
inhibitors  of  the  enzymes,  and  the  combination  of  anticancer  drugs  with 
modulating agents, appear to be interesting avenues to obtain better therapeutic 
effects and/or more tolerable toxicities in the treatment of patients with tumours.
77
It  should  be  emphasized  that  the  relevance  of  studies  performed  on 
experimental animals to increase our knowledge of metabolic pathways cannot be 
questioned. The relative importance of salvage and de novo pyrimidine synthesis 
between species, on the other hand, must be carefully considered when trying to 
apply results obtained in different species to the clinical setting (31). Furthermore 
since evident differences in metabolism exist not only between normal tissues, 
but also between experimental tumour models, the relevance of results obtained 
in just one system for other situations is necessarily limited. 
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Abstract
5-Fluorouracil (5FU) shows a steep dose response curve
in several experimental systems, but the clinical use of
high doses is hampered by the toxic side effects of this
drug. Uridine diphosphoglucose (UDPG) rescue allows
an increase in the maximum tolerated dose of 5FU in
mice from 100 (FU100) to 150 mg/kg (5FU150+UDPG) and
the higher dose is more effective than the standard treat-
ment against several tumors. In the present paper we
report on the effect of high-dose 5FU on thymidylate syn-
thase (TS) levels and on 5FU incorporation into RNA. In
the resistant murine tumor (Colon 26A) high-dose 5FU
inhibited TS catalytic activity 8 h after treatment (4-fold;
p = 0.00041) and the inhibition persisted until day 3
(p ! 10–4). Standard-dose 5FU did not significantly inhibit
TS activity. In a relatively sensitive tumor (Colon 26-10),
there was no difference in the initial extent of TS inhibi-
tion by the two 5FU doses, but TS was still inhibited (2-
fold) on day 3 after (5FU150+UDPG) while it was within
the normal range after 5FU100. In both tumor types TS
activity showed an impressive rebound (3-fold) on days
3–7, and this occurred after both 5FU doses. In Colon
26A, however, a new 5FU injection on day 7 was still able
to inhibit TS but not as effectively as the first dose. 5FU
incorporation into RNA reached similar peak values
(8 pmol/Ìg RNA) after the two 5FU doses, but the clear-
ance was faster in mice receiving UDPG rescue. We con-
clude that UDPG does not interfere with the extent of TS
inhibition by 5FU, but UDPG allows the use of a higher
dose of 5FU resulting in enhanced TS inhibition. UDPG,
however, increases 5FU clearance from RNA. In this
experimental system the inhibition of TS seems essen-
tial in order to obtain a good antitumor activity, while
5FU incorporation into RNA does not seem to play a role
in the antitumor activity of 5FU. Since preliminary results
indicate that UDPG is well tolerated by patients, the use
of higher 5FU doses may improve the response rate of
human tumors.
Copyright © 2002 S. Karger AG, Basel
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Introduction
Similar to other anticancer drugs, 5-fluorouracil (5FU)
presents a dose-dependent antitumor effect [1]. Unfortu-
nately the use of higher doses also increases the hemato-
logical and gastrointestinal toxicity of the drug [2]. Uri-
dine (Urd) and its derivatives may reduce the toxic side
effects of 5FU and allow an increase of 50% in the maxi-
mum tolerated dose not only in mice [3–7] and rats [8] but
also in clinical studies [9–11]. Unfortunately the clinical
use of Urd has been limited by its side effects [12, 13].
Urd diphosphoglucose (UDPG) has been tested as an
alternative to Urd and does not show the clinical toxicity
of the parent compound [14]. In a previous study we have
shown that UDPG is as effective as Urd in reducing the
toxicity of 5FU and that it does not interfere with the anti-
tumor activity of 5FU [15].
The antiproliferative effect of 5FU depends on its
interference with RNA and DNA metabolism and on the
inhibition of thymidylate synthase (TS) [16]. The relative
importance of the different targets may depend on the
schedule of administration [17], on the characteristics of
the tumor [18], on the dose, and on the type of prodrug
[19]. It has been demonstrated that Urd rescue allows the
administration of a higher dose of 5FU, that the incorpo-
ration of 5FU into RNA was increased [20], but that TS
inhibition was not affected. However, in these studies the
time course was limited, while the retention of TS inhibi-
tion may be a more important additional parameter for
the antitumor effect [19, 21]. Another important aspect in
the sensitivity to 5FU is the extent and onset of TS induc-
tion, which can be prevented by leucovorin [21]. At a low-
dose continuous infusion the onset of induction of TS was
associated with tumor relapse [22].
In the present study we evaluated whether the im-
proved antitumor effect of a high-dose 5FU followed by
UDPG rescue compared to standard dose 5FU is related
to improved TS inhibition or to a higher incorporation of
5FU into RNA. For this purpose, and to determine
whether the effect of a high dose would be selective, we
used two murine tumors: Colon 26A which is relatively
resistant to 5FU and showed a better response to high-
dose 5FU, and Colon 26-10, a sensitive variant [23].
Materials and Methods
Chemicals
5FU was obtained from ABIC (Netanya, Israel). Leucovorin (LV)
was prepared as a racemic mixture by the Department of Pharmacy
of the University Hospital (Amsterdam, The Netherlands). UDPG
was provided by Boehringer-Mannheim Italia (Monza, Milan, Italy)
as a powder and was resuspended in normal saline immediately
before injection. [6-3H]-FdUMP (specific activity 20 Ci/mmol) was
purchased from Moravek Biochemicals Inc. (Brea, Calif., USA) and
[5-3H]-dUMP (specific activity 10.9 Ci/mmol) from Amersham In-
ternational Little Chalfont, UK). dl-Tetrahydrofolate (Sigma Chemi-
cals, St. Louis, Mo., USA) was converted into 5,10-methylenetetra-
hydrofolate by addition of formaldehyde [24]. All other chemicals
were of analytical grade and are commercially available.
Animals and Tumors
Colon 26-A and Colon 26-10 tumors were maintained in Balb/c
mice (Harlan/cbp, Zeist, The Netherlands): these tumors have been
thoroughly studied and their characteristics have been described:
Colon 26-A is relatively resistant to 5FU100, which only causes a lim-
ited delay in tumor growth, while Colon 26-10 is remarkably more
sensitive to standard treatment, while several complete responders
were found (table 1) [3, 23].
Tumors were transplanted subcutaneously on the two flanks in
the thoracic region in fragments of 1–5 mm3. Tumor size was mea-
sured by caliper (length ! width ! depth ! 0.5) and treatment was
started when the volume was 50–150 mm3. Animals bearing Colon
26-A were sacrificed 1 day before presumed death due to cachexia,
Colon 26-10 mice were sacrificed in case the tumor volume exceeded
1,000 mm3.
The evaluation of antitumor activity was based on the growth
delay factor (GDF) calculated from the mean tumor doubling time
(TD) of treated tumors and controls according to the formula GDF =
(TDtreated – TDcontrols)/TDcontrols.
5FU was administered intraperitoneally (i.p.) as a weekly bolus at
the dose of 100 mg/kg (5FU100) or at the dose of 150 mg/kg (5FU150)
followed by UDPG 2,000 mg/kg 2, 24 and 30 h after 5FU. LV was
injected in two doses of 50 mg/kg: one was given 1 h before 5FU, and
the second was given together with 5FU. All drugs were given as an
i.p. bolus. Since in our previous studies [15] on the toxicity and the
antitumor effect of 5FU B UDPG, treatment was administered ev-
ery week for 21 days, we gave a second dose to Colon 26-10 on
day 7 in order to evaluate the effect of this 5FU dose on TS activity.
The antitumor activity of 5FU150 with no UDPG rescuing could not
be studied since this dose is 50% higher than the maximum tolerated
dose and, as already reported, is rapidly fatal [15].
TS Assays
TS assays were performed as previously described [21, 22, 25].
Tumors were removed at different time points after treatment, fro-
zen in liquid nitrogen, pulverized [26] and used for enzyme determi-
nation and to measure 5FU incorporation in RNA. The FdUMP-
binding sites were measured with the [6-3H]-FdUMP-binding assay,
while the catalytic activity was calculated from the amount of 3H2O
released in the conversion of [5-3H]-dUMP into dTMP. This was
performed with optimal (10 ÌM ) and suboptimal (1 ÌM, which is
around the Km for TS) dUMP concentrations.
Treatment with 5FU results in formation of FdUMP which
together with 5,10-methylenetetrahydrofolate and TS forms a stable
ternary complex. The efficacy of TS inhibition is determined by the
extent of ternary complex formation. Only free TS (not bound in the
ternary complex) is able to catalyze dUMP conversion to dTMP (TS-
residual) or to bind additional FdUMP (TS-free). This is considered
as the inhibited TS. In order to determine the total amount of TS
protein in tumors FdUMP has to be dissociated from this complex.
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Table 1. Summary of antitumor activity of 5FU100 and 5FU150 and
5FU150+UDPG rescue against Colon 26A and Colon 26–10
TD, days GDF
Colon 26A
Control 1.9
5FU100 8.6* 3.4
5FU150+UDPG 13.8*, # 6.1
Colon 26–10
Controls 3.8
5FU100 110* 110
5FU150+UDPG 110* 110
TD = Tumor doubling time is calculated from the first day of
treatment; GDF = growth delay factor. In Colon 26-10 the treated
tumors did not double because of their sensitivity to the treatment.
Data are in part from Codacci-Pisanelli et al. [15].
* Significantly different from controls: p ! 0.001.
# Significantly different from 5FU100: p ! 0.05.
After dissociation the total capacity of TS to convert dUMP to
dTMP (TS-total) can be measured, while all binding sites of TS are
available to bind FdUMP (TS-tot). Dissociation was performed as
described previously by incubation at pH 7.85 with excess dUMP
[21] and was only performed in samples obtained after more than 3
days because previous studies demonstrated that before this time TS
levels were not upregulated compared to the control [21]. In tumors
from treated mice TS-tot or TS-total can be lower than in control
tumors because of increased degradation of TS protein and de-
creased synthesis, while at later time points TS synthesis can be
induced.
Analysis of FdUMP Concentration
FdUMP concentrations were measured as previously described
[21] by means of a dilution assay based on the capacity of FdUMP
present in the tumors to inhibit the binding of radioactively labelled
FdUMP to Lactobacillus casei TS.
5FU Concentration in RNA
5FU incorporation into RNA was performed in RNA isolated
from the first precipitation step, as already described [27]: the assay
is based on the degradation of RNA containing FUTP to 5FU by
incubation with RNAse and, alkaline phosphatase and Urd phos-
phorylase. 5FU was then extracted, derivatized and measured by gas
chromatography coupled to mass spectrometry [26, 27].
Statistics
Potential differences between the various treatments were evalu-
ated using Student’s t test for unpaired samples. A p ! 0.05 was con-
sidered statistically significant.
Results
Antitumor Activity of High-Dose 5FU
High-dose 5FU (5FU150) with UDPG rescue was more
effective than standard-dose 5FU in both tumor types (ta-
ble 1). Schedules for optimizing the treatment in Colon
26A have been previously published [15]. In colon 26-10,
that was included as a sensitive control, both treatments
were highly effective in terms of tumor growth compared
with untreated controls (p always ! 0.026). High-dose
5FU could not be tested in the absence of UDPG rescue
because of the lethal toxicity of 5FU150 alone. UDPG
itself did not affect tumor growth.
TS Inhibition
In Colon 26A a standard dose of 5FU did not have any
effect on TS catalytic activity, while high-dose 5FU fol-
lowed by UDPG rescue caused a rapid decrease (fig. 1A).
The difference between these tumors (5FU150) and both
untreated controls and tumors treated with 5FU100 was
statistically significant already 8 h after 5FU injection,
while the enzyme remained inhibited until day 3 (p al-
ways ! 0.001). On day 7 after 5FU injection TS activity
was significantly higher than in untreated controls: this
occurred both with 5FU100 and with 5FU150+UDPG (p !
0.001). This phenomenon persisted until day 10 (p =
0.0014).
When TS levels were evaluated according to FdUMP
binding capacity (fig. 1B) both standard- and high-dose
5FU caused a similar decrease in TS. Enzyme levels went
back to normal values on day 3 after 5FU100, but after
5FU150+UDPG this only happened on day 7. In this assay
enzyme induction was only seen on day 10 after both dose
levels.
5FU is often administered as a weekly injection; we
therefore investigated whether a second dose of 5FU giv-
en on day 7 affected TS levels. TS levels at this time point
were 3-fold higher than before treatment. The catalytic
activity and the FdUMP binding were effectively reduced
on days 7+1 and 7+3 in comparison with results obtained
on day 7, but not in comparison with the TS activity of
untreated controls (fig. 1A).
When TS levels were considered in terms of all en-
zymes present (fig. 2) it was evident that 5FU150+UDPG
not only inhibited TS, but actually reduced the total
amount of enzyme. This reduction was significant not
only in comparison with controls, but also with tumors
treated with standard-dose 5FU. However, both on
days 7 and 10 total TS levels, evaluated either as FdUMP
binding or catalytic activity, were increased in compari-
106
366 Oncology 2002;62:363–370 Codacci-Pisanelli/Van der Wilt/Smid/
Noordhuis/Voorn/Pinedo/Peters
Fig. 1. Effect of 5FU100 and 5FU150+UDPG
treatment on TS levels in Colon 26A de-
termined as residual catalytic activity with
10 ÌM dUMP (A) and as free FdUMP-bind-
ing sites (B). Data represent TS levels pres-
ent after inhibition. Mice received one or
two weekly treatments with 5FU at 100 or at
150 mg/kg with UDPG rescue. Tumors were
excised at the indicated time points. 7+1 and
7+3 are the samples taken 1 and 3 days after
the second treatment. Results are means B
SD of 3–5 tumors for each point. Control
levels (i ), inhibited residual and free TS
levels after 5FU100 treatment (W) and after
5FU150+UDPG treatment (g ). * Signifi-
cantly different from controls. 
son with untreated controls after both 5FU doses (p !
0.01). A second injection on day 7 prevented this induc-
tion (data not shown).
In Colon 26-10, which is sensitive to 5FU, TS was
effectively inhibited by both standard- and high-dose
5FU in the first 24 h (fig. 3). After 5FU100 TS partially
recovered on day 3, and rebounded on days 7 and 10 (p !
0.001). After 5FU150+UDPG TS was still inhibited on
day 3 (p = 0.03), but in contrast to 5FU100 it was not sig-
nificantly higher than in untreated controls on day 7. A
rebound was only observed on day 10. The increase in the
total amount of TS present in Colon 26-10 was lower than
in Colon 26-A (fig. 2), and this phenomenon tended to be
less pronounced after 5FU150+UDPG.
FdUMP Concentrations
The concentration of FdUMP measured in the tumor
samples of Colon 26-10 is similar for the high and the low
dose of 5FU (fig. 4), and in both cases it was below detec-
tion limit 48 h after treatment. In Colon 26-A similar lev-
els were observed (data not shown).
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Fig. 2. Induction of TS activity shown as
total (uninhibited) TS catalytic activity in
Colon 26A and Colon 26-10 tumors. Values
are means B SD and are normalized to TS
levels in control tumors (i; 100%). W =
5FU100 treatment; g = 5FU150+UDPG
treatment. Significantly different from con-
trols (* p ! 0.001); significantly different be-
tween 5FU100 and 5FU150+UDPG (# p !
0.01).
Fig. 3. Effect of 5FU100 (W) and
5FU150+UDPG (g ) treatment on TS-
FdUMP-binding capacity in Colon 26-10.
Data represent TS levels present after inhibi-
tion (free FdUMP-binding sites). Mice re-
ceived 5FU at 100 or 150 mg/kg with UDPG
rescue. Tumors were excised at the indicated
time points. Results are means B SD of 3–5
tumors for each point. * Significantly differ-
ent from controls. i = Control levels.
Incorporation of 5FU into RNA
The incorporation of 5FU in RNA was studied in both
the sensitive Colon 26-10 and the more resistant Colon
26A after injection of high-dose 5FU (fig. 5). In Colon
26A the highest incorporation was detected 2 h after 5FU
administration. Following the injection of UDPG the
incorporation decreased but after the last injection it
increased again. After day 2 the amount of 5FU in RNA
slowly decreased and was still measurable on day 10.
The comparison of 5FU incorporation into RNA with
Colon 26-10 demonstrated that 5FU150+UDPG resulted
in a higher incorporation in RNA, but after UDPG
administration was rapidly cleared, so that on day 7 levels
are close to the limit of detection for 5FU150+UDPG,
while 5FU in RNA was still measurable in tumors of mice
treated with 5FU100 (fig. 5).
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Fig. 4. FdUMP concentrations in Colon 26-10 treated with 5FU100
(P) or 5FU150+UDPG ($). Values are means B SD of 3–5 tumors
for each point. ww = Wet weight.
Discussion
High-dose 5FU followed by UDPG rescue has a better
antitumor activity than standard-dose treatment. The
results presented in this article demonstrate that this is
associated with a more effective inhibition of TS and that
TS is the main target of 5FU; while incorporation of 5FU
into RNA apparently did not contribute to the antitumor
effect. Besides the extent of TS inhibition, its duration
and delay of TS induction seem equally important for
effective antitumor activity. The time required for en-
zyme activity to recover and the extent of induction may
explain the different sensitivities of Colon 26A and Colon
26-10 to 5FU treatment and the better effect of the higher
dose. The 5FU-sensitive and resistant tumors are differ-
ent in their initial extent of TS inhibition and its duration,
which was longer in the sensitive tumor. Especially for the
high-dose 5FU these differences seem more pronounced.
In both models TS activity showed a rebound 3–7 days
after exposure to the two 5FU doses reaching levels that
are 3- to 5-fold higher than in untreated controls. This
observation in consistent with previous data obtained in
mice after treatment with bolus 5FU [21, 28] and with
continuous infusion [22]. A rebound of TS has been
observed using different methodologies, in general the
most pronounced TS induction was found when TS pro-
Fig. 5. 5FU incorporation in RNA extracted from Colon 26A (A)
and from Colon 26-10 (B) treated with standard- or high-dose 5FU
followed by UDPG rescue. P = 5FU100; $ = 5FU150+UDPG. Values
are means B SD of 3–5 tumors for each point.
tein was measured [29]. However, usually this did not
give information on the functional activity of TS in the
cell. Actually in WiDr cells TS protein induction was still
associated with an almost complete absence of TS catalyt-
ic activity in the cell [30]. TS enzyme induction may
influence the effect of treatment. Using the weekly sched-
ule of 5FU the second injection is given when TS levels
are markedly increased. In Colon 26A this new injection
still inhibits TS, but not to the same extent as the first
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dose. In Colon 26-10 the TS rebound occurs on day 7 after
5FU100, but only on day 10 after 5FU150. A high enzyme
activity present at the moment of the second treatment
may worsen the effect of treatment and explain the differ-
ent antitumor activity of the two doses.
In experimental systems it has been demonstrated that
a single measurement of TS may be inadequate since
enzyme levels can increase during treatment and cause
resistance. This has been observed in vitro [30, 31] and in
vivo [19, 21, 22, 28]. According to the model proposed by
Chu et al. [29], this may be caused by transient regulation
of TS translation by its own protein or due to enzyme sta-
bilization [32] since TS is trapped in the ternary complex
which is quite stable. Under physiological conditions
there is an equilibrium between TS mRNA and TS pro-
tein, however FdUMP binding to TS results in a structur-
al change in the protein leading to an altered binding of
TS to its mRNA and in an uncontrolled new synthesis of
protein. In case sufficient FdUMP is available this may
still result in complete inhibition of catalytic TS activity,
but also to trapping of TS in the ternary complex. Since
this induction of TS is a potential cause for resistance to
5FU it is of utmost importance to prevent or reduce this
induction. The present study shows that the induction
could be partially prevented by a new 5FU dose, and pre-
vented more efficiently by a high dose. Administration of
this high dose of 5FU was only possible when it was fol-
lowed by an appropriate rescue agent, in this study
UDPG. Since LV was also able to enhance the antitumor
activity of 5FU + UDPG, a triple combination seems very
attractive, since LV not only prevents TS induction [21]
but also enhances TS inhibition [33]. The combination
LV and Urd indeed enhanced TS inhibition more than
each compound alone (data not shown). This study pro-
vides a mechanistic explanation for the better antitumor
effect which is observed at higher dose of 5FU, both
experimentally [5] and clinically [1, 34]. Prolonged TS
inhibition may also be the mechanistic explanation for
the efficacy of high-dose 24-hour infusion in combination
with LV [35].
In vitro studies frequently demonstrated a potential
role of either TS inhibition or 5FU incorporation into
RNA for the antitumor activity [16–18] which might in
part depend on the duration of exposure. However, in
vivo studies indicated that incorporation of 5FU into
RNA was predominantly responsible for toxicity [5, 36]
while recently this could be attributed to 5FU-RNA-
induced apoptosis in mucosa, which could be rescued by
Urd [37]. In vivo studies initially demonstrated that high-
dose 5FU increased 5FU incorporation into RNA of
tumors [20] without affecting TS. However, the relatively
short time period of sampling precluded evaluation of
prolonged TS inhibition and induction. A high-dose 5FU
administration, enable by Urd rescue, resulted in a proto-
col that is more active and less toxic than standard dose
5FU [9, 11]. Although this study was performed with
experimental murine tumors, the data provide a biochem-
ical rationale for Urd rescue, which are not only support-
ed by other experimental studies but also by data obtained
in patients with whom a clear relationship was found
between the response to 5FU and TS inhibition [25], but
not for 5FU incorporation into RNA [38]. UDPG rescue
can be facilitated by oral administration [15], while pre-
liminary clinical results with UDPG [14] and the Urd
prodrug triacetyluridine [11, 39] indicate that an effective
rescue is possible. The selective increase in TS inhibition
in the tumor and prevention of its induction offer new op-
portunities for the use of higher 5FU doses in the clinic.
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Chapter   10
Summarising  Discussion
The fight against cancer is based on several elements: prevention, early 
diagnosis, surgical removal, radiation treatment and drug therapy. The goal is 
to increase cure and to reduce the consequences of treatment. Progress has 
been observed in all these aspects, even if to a different extent in the different 
tumour types. 
Concerning colorectal cancer, screening with colonoscopy after the age of 
fifty represents a very effective technique, but it is not widely accepted by the 
general population. This is one of the reasons why this remains a very common 
cancer even if at present it is often diagnosed at a relatively early stage. In this 
situation it is possible to cure the majority of patients by the surgical removal 
of the tumour. When cancer has spread to the regional lymph nodes, however, 
survival can be improved by the postoperative administration of chemotherapy 
(adjuvant treatment). Even when colorectal cancer has spread to the liver or to 
the  lungs,  metastases  can  be  resected  with  excellent  results.  In  many 
metastatic patients, however, chemotherapy is the only available treatment. 
For many years the only drug with a consistent activity against colorectal 
cancer was 5-Fluorouracil (FU) and this is the reason why this drug has been 
extensively studied in this disease. It was necessary to use FU at its best in 
order to improve the meagre results. Today other conventional drugs have been 
added to the medical treatment of colorectal cancer (Irinotecan, Oxaliplatin) 
and monoclonal antibodies (Cetuximab, Panitumumab, Bevacizumab) but FU 
still represents a necessary element of treatment. 
Unfortunately the list of ineffective drugs that have been tested against 
colorectal  cancer   is  very  long:  not  only  other  fluoropyrimidines,  but  also 
anticancer  drugs  that  are  very  effective  against  other  cancers  and,  more 
recently, inhibitors of tyrosine kinases that act on the epidermal growth factor 
receptor pathway and/or on  angiogenesis. 
The first successful method to improve FU activity in colorectal cancer 
was through “modulation”. This term indicates the possibility of influencing the 
activity of FU by providing cofactors that would preferentially direct its activity 
against a specific target. As discussed in chapter 2 several agents have been 
proposed  as  “modulators”  of  FU:  a  general  principle  is  however  that  these 
agents  should  have  no  or  limited  anticancer  activity  by  themselves.  For 
methotrexate a direct modulation is plausible, even if this role might be played 
by  the  administration  of  folinic  acid  that  was  given  as  a  rescue  from 
Methotrexate toxicity.
Even  if  chapter  2  was  written  many  years  ago,  no  new agents  have 
appeared as modulators of intravenous FU since then, and only folinic acid is 
still  widely  used  today  in  clinical  practice.   It  is  interesting  to  note  that 
Cisplatin was proposed as a modulator of FU activity: today this drug is only 
very rarely used in colorectal cancer, while Oxaliplatin is commonly associated 
with FU, but with no claim of a modulating role. 
5-Fluorouracil  is  an  interesting  drug  not  only  due  to  its  complex 
metabolism and to the presence of multiple sites of antiproliferative action in 
the cell, but also because it is rapidly cleared from plasma.  The half life of the 
parent compound is 10-15 minutes. This makes it an ideal candidate for the 
prolonged  administration  through  intravenous  infusion.  The  widespread 
clinical  use  of  this  schedule,  however,  was  only  possible  when  small  and 
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convenient infusion pumps became available:  prolonged  FU infusion (lasting 
several weeks) was compared with standard i.v. push. Clinical trials in patients 
gave  disappointing  results:  even  if  the  response  rates  were  higher  for  the 
prolonged infusions, survival was not improved. The main difference, however, 
consisted in a lower haematological toxicity of infused FU: this made it very 
suitable for combination with myelotoxic agents and/or with radiotherapy. It 
was even suggested that bolus and infused FU were almost two different drugs 
and the two modalities were combined in protocols that had different fortunes. 
The prolonged infusion of FU in patients was technically possible much 
earlier  than it  was in  experimental  animals.  We  were  among the  first  that 
studied the possibility of reproducing the very long (21 days) infusion of FU in 
mice using subcutaneously implanted pellets. We demonstrated that the drug 
was actually delivered during the entire period and that plasma levels were in 
the  micromolar  range.  Interestingly,  we showed that  also in the  mouse FU 
concentrations vary with a circadian rhythm: this had already been seen in 
humans  receiving  FU by  continuous  infusion,  and is  due  to  the  circadian 
variation in the activity of DPD, the main enzyme in FU catabolism. 
We also studied the possibility  of  using folinic  acid as a  modulating 
agent  of  infused  FU.  Similarly  to  what  was  demonstrated  in  humans,  this 
combination results in increased gastrointestinal toxicity and does not improve 
the antitumour activity of FU infusion. This is consistent with the observation 
that folinic acid does not increase TS inhibition, but rather prolongs FdUMP 
binding to TS: this effect is not relevant when FdUMP concentrations in tissues 
are constantly maintained thanks to the prolonged administration of FU.   
When FU infusion was compared with bolus treatment in mice implanted 
with different tumour types results again reproduced the clinical observations: 
tumour volume was more effectively decreased by infusion, but survival was 
not different.  After a few days in fact tumours started to grow again at a rate 
similar to that of untreated controls. Biochemical analysis of tumour tissues 
showed that TS activity, that was reduced during the first days of treatment, 
showed an impressive rebound after 7-10 days of FU infusion. 
We  continued  to  study  the  pharmacological  aspects  of  bolus  FU  in 
humans: the standard dose had already been extensively studied, but few data 
existed  concerning  the  administration  of  higher  drug  doses.  We  therefore 
analysed data obtained from patients enrolled in a trial of escalating doses of 
FU. We showed that the main pharmacological parameter, AUC, was correlated 
with peak plasma concentration and that it was possible to accurately predict 
plasma AUC using the concentration measured at 30 minutes after bolus FU 
injection. 
In  this  trial  we  also  observed  a  patient  who  had  severe  unexpected 
toxicity even at very low FU doses: this patient was later shown to have an 
eightfold  reduction  in  the  activity  of  DPD,  the  rate-limiting  enzyme  in  FU 
catabolism.  His  AUC,  and  the  danger  of  significant  toxicity,  could  also  be 
accurately predicted by FU concentration at 30 minutes. 
Fluorouracil  is  an  antimetabolite  that  inhibits  cell  proliferation  by 
interfering  with  the  use  of  the  physiological  counterparts:  Uridine  and  its 
derivatives. In the case of other antimetabolites, it has been demonstrated that 
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it  is  possible  to  increase  the  tolerated  drug  dose  by  providing  high 
concentrations  of  the  rescuing  physiological  metabolite.  In  the  case  of 
methotrexate it is possible to administer very high doses with tolerable toxicity 
when folinic acid is  given starting 6 hours after methotrexate infusion. The 
high  concentrations  of  methotrexate  that  can  be  safely  reached  with  this 
protocol  may  be  able  to  overcome  cell  resistance  linked  to  poor  trans-
membrane transport. 
A similar strategy has been proposed for fluorouracil by using Uridine as 
a  rescuing  agent.  A  further  advantage  was that  the  administration of  high 
doses  of  Uridine  in humans was already used to treat  a specific  metabolic 
alteration. 
In vitro studies on uridine rescue were very promising, but the administration 
of pharmacological doses of uridine to experimental animals resulted in fever or 
hypothermia and diarrhoea. A similar effect was seen in humans: the doses of 
uridine needed to rescue normal tissues from FU toxicity, in fact, were very 
high, and resulted in intolerable toxicity.
Considering the interesting in vitro results obtained with uridine, but the 
difficulties caused by its administration humans, the next step was to identify 
a  form of  “prodrug”  of  Uridine  that  might  be  administered with lower  side 
effects and increase Uridine concentration in plasma and in normal tissues. We 
focussed on Uridine diphosphoglucose. 
This  molecule  is  used  in  several  biochemical  reactions  as  a  glucose 
donor, for example in the biosynthesis of glycogen in the liver. We studied the 
effect of UDPG rescue after high-dose FU in mice: UDPG was administered in 
three doses starting two hours after FU bolus. We showed that FU toxicity in 
normal tissues was reduced and that it was possible to increase the MTD of FU 
by  50% (from 100 to  150  mg/kg/week)  and that  this  treatment  was more 
effective than the standard dose against three murine colon tumours (Colon 
26, Colon 26-10 and Colon 38). In subsequent experiments we demonstrated 
that UDPG rescue, at the schedule used in our experiments, did not interfere 
with the antitumour activity of FU: when standard FU dose (100 mg/kg/week) 
was administered with or without UDPG rescue, in fact, the antitumour activity 
did not change. 
The  next  step  was  to  investigate  the  biochemical  explanation  of  the 
rescuing activity of UDPG from FU toxicity that did not affect the antitumour 
activity.  The  high-dose  FU followed  by  UDPG rescue  resulted  in  prolonged 
inhibition of TS activity, and UDPG allowed a faster clearance of FUTP from 
cellular  RNA.  This  element  is  a  further  demonstration  that  in  this  tumour 
model the antitumour activity of FU is due to its interference with TS activity, 
while  FUTP incorporation into RNA is  mainly responsible  for  the toxic  side 
effects of treatment. 
Fluorouracil is being used since 50 years, and its role in the treatment of 
many tumour types remains pivotal. New drugs are being combined with it, but 
it has never been completely replaced. Many aspects of its pharmacology are 
not yet fully described, and its complex metabolism  proved to be an important 
element in order to improve its antitumour activity.  Several drugs have been 
combined with 5FU in the treatment of colorectal cancer: at present the most 
widely  used  schemes  are  FOLFIRI  (with  Irinotecan)  and  FOLFOX  (with 
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Oxaliplatin). Also these polychemotherapy schemes are being improved, and we 
now use a modified version that is indicated as mFOLFOX-6. An improvement 
in  5FU dosing should be possible  if  techniques such as Therapeutic Drug 
Monitoring are implemented. This is also valid for the oral administration of 
molecules that act as a prodrug for 5FU: Capecitabine, UFT and S-1. These 
compounds  mimick  the  prolonged  infusion  of  5FU  since  they  provide  a 
constant exposure of tissues to the active metabolites but do not require the 
disadvantages of pumps and of a permanent venous access. 
Last but not least “modern” therapies based on the use of (Tyrosine Kinase 
inhibitors, monoclonal antibodies) still require the presence of 5FU although 
the optimal schemes of administration still need to be determined.  
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nederlandse 
Samenvatting 
In  de  strijd  tegen  kanker  kunnen  we  meerdere  aspecten  onderscheiden: 
preventie,  vroege  diagnose,  operatieve  verwijdering,  bestraling  en 
behandeling met geneesmiddelen. Het uiteindelijke doel is om de patiënt te 
genezen.  Daarnaast  streven  we  ernaar  om  de  bijwerkingen  van  de 
behandeling zoveel  mogelijk  te  verminderen.  Bij  meerdere soorten kanker 
(borstkanker,  dikke  darmkanker)  is  een  enorme  vooruitgang  geboekt,  bij 
andere (alvleesklier, hersentumoren) helaas niet.
Bij  de  behandeling  van  dikke  darm  kanker,  ook  colon  kanker 
genoemd, is screening met behulp van colonoscopie bij mensen ouder dan 
50  een  zeer  effectieve  methode  om  de  tumor  vroeg  op  te  sporen.  Deze 
screening wordt (nog) niet algemeen gebruikt. Dikke darm kanker komt vrij 
veel  voor,  maar  wordt  gelukkig  vaak vrij  vroeg gevonden.  In dat  geval  is 
genezing  door  operatieve  verwijdering  mogelijk.  Als  de  tumor  zich  echter 
verspreid (gemetastaseerd)  heeft  naar de lymfeklieren wordt  de operatieve 
verwijdering  van  de  tumor  en  de  lymfeklieren,  vaak  gevolgd  door 
chemotherapie,  adjuvante  therapie  genoemd.  Zelfs  als  de  tumor  zich 
verspreid heeft naar de lever of de longen, kunnen deze metastases in een 
aantal gevallen met succes verwijderd worden, maar vaak is chemotherapie 
in deze patiënten de enige behandeling.
Gedurende veel jaren was het geneesmiddel 5-fluorouracil (5FU) het 
enige  beschikbare  middel  met  een  duidelijke  effectiviteit.  Uitgebreid 
onderzoek, o.a. binnen de afdeling Medische Oncologie van het VU Medisch 
Centrum, heeft  er  toe  geleid dat  de resultaten van behandeling met  5FU 
sterk verbeterd zijn. Vooral het optimaliseren van het behandeling schema 
met leucovorin en het toepassen van de platina verbinding oxaliplatin, en de 
topoisomerase  1  remmer,  irinotecan,  speelden  hierbij  een grote  rol.  Deze 
schema’s  staan  bekend  als  FOLFOX  (5FU,  leucovorin,  oxaliplatin)  en 
FOLFIRI  (5FU,  leucovorin,  irinotecan).  5FU  bleef  en  is  nog  steeds  een 
essentieel bestanddeel van de behandeling.
De lijst van middelen die getest zijn om de behandeling van 5FU te 
verbeteren is  erg  lang.  Helaas  bleken  de  positieve  resultaten,  zoals  vaak 
gevonden  in  model  systemen,  niet  vertaald  te  kunnen  worden  in  een 
effectieve  behandeling  van  de  patiënt.  De  reden  hiervan  was  vaak  een 
verkeerd model systeem. Alleen oxaliplatin en irinotecan konden succesvol in 
de  kliniek  geïntroduceerd  worden.  Momenteel  wordt  een  andere  groep 
nieuwe  geneesmiddelen,  de  signaal  transductie  remmers,  met  wisselend 
succes  onderzocht.  Deze  middelen  hebben  als  gemeenschappelijke 
eigenschap  dat  ze  de  cellulaire  overleving  routes  kunnen  remmen.  Een 
subgroep,  de  tyrosine  kinase  remmers,  kan  bijvoorbeeld  de  signaal 
transductie route van de epidermale groeifactor receptor (EGFR) remmen. 
Voorbeelden  van  zulke  geneesmiddelen  die  gebruikt  worden  bij  de 
behandeling  van  dikke  darm  kanker,  zijn  de  monoklonale  antilichamen, 
cetuximab  and  panitumumab.  Daarnaast  kunnen  deze  tyrosine  kinase 
remmers de angiogenese remmen. Tumor angiogenese is een proces waarbij 
bloedvaten  in  de  tumor  worden  aangemaakt,  om  de  tumor  van 
voedingsstoffen en zuurstof te voorzien. Het afsnijden van deze route met 
deze remmers is een nieuwe alternatieve manier om de groei van de tumor te 
remmen.  Een  voorbeeld  hiervan  is  het  monoklonaal  antilichaam 
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bevacizumab,  dat  de  groeifactor,  Vascular  Endothelial  Growth  Factor 
(VEGF), neutraliseert.
De eerste succesvolle benadering om de werking van 5FU te verbeteren 
wordt “modulatie” genoemd (Hoofdstukken 2 en  6). De bedoeling hiervan is 
dat  het  metabolisme van 5FU zodanig wordt  beïnvloed,  dat  de antitumor 
activiteit  word verbeterd en/of de bijwerkingen worden verminderd. Soms 
hebben deze “modulatoren” zelf geen antikanker activiteit, maar soms wel. 
Een aantal van deze modulatoren, zoals ontwikkeld tot het midden van de 
jaren negentig,  worden in  Hoofdstuk 2 behandeld.  Van de  modulatoren, 
zoals beschreven in dit hoofdstuk heeft alleen leucovorin, een folium zuur 
analoog, de tand des tijds overleefd. Leucovorin stimuleert de werking van 
5FU, maar heeft  bij  een ander geneesmiddel,  het antifolaat methotrexaat, 
juist een beschermende werking. Een ander geneesmiddel wat veel gebruikt 
wordt in de combinatie met 5FU is cisplatin; deze combinatie wordt echter 
alleen  bij  de  behandeling  van  hoofd-hals  kanker  met  succes  toegepast. 
Cisplatin wordt echter veel gebruikt bij de behandeling van andere tumoren, 
zoals long-, eierstok-, teelbal-, maag- en blaaskanker. Daarom werd cisplatin 
ook bij  dikke darm kanker onderzicht,  maar bleek ineffectief  te zijn.  Een 
analoog, oxaliplatin, was echter uitermate succesvol en vormt onderdeel van 
de combinatie FOLFOX.
5FU  is  een  interessant  geneesmiddel  vanwege  zijn  ingewikkeld 
metabolisme en de vele aangrijppunten in de cel, die gezamenlijk hebben 
bijgedragen en zijn succes. 5FU wordt na een bolus injectie echter snel uit 
het lichaam verwijderd, met een halfwaarde tijd van slechts 10-15 minuten. 
Daarom is 5FU, zoals beschreven in Hoofdstukken 3 en 4 een ideaal middel 
voor toediening via een continu infuus. Het standaard toepassen van deze 
behandeling  bleek  echter  pas  mogelijk  toen  kleine  en  gemakkelijk 
hanteerbare pompen beschikbaar kwamen. Toen konden langdurige infusen 
van 5FU (enkele weken) vergeleken worden met een bolus injectie in de ader. 
De eerste klinische studies waren echter teleurstellend: de response ratio’s 
waren weliswaar hoger voor de infusen, maar de uiteindelijke overleving niet. 
Het  belangrijkste  verschil  zat  echter  in  de  bijwerkingen,  die  voor  de 
hematologische toxiciteit, minder was bij de infusen. Dit maakte de infusen 
uitermate geschikt voor combinaties met geneesmiddelen die hematologische 
toxiciteit veroorzaken. Ook zijn de continue infusen uitermate geschikt voor 
combinaties met bestraling,  zoals gebruikt bij  de behandeling van rectale 
(endeldarm) kanker. Men zou de bolus injecties en de infusen zelfs als twee 
verschillende geneesmiddelen kunnen beschouwen.
Om  te  kunnen  begrijpen  wat  de  verschillen  zijn  tussen  deze  twee 
behandeling  was een proefdier  model  nodig.  Dit  was technisch  erg  lastig 
totdat  we  de  beschikking  kregen  over  onderhuids  geplaatste  pellets, 
waarmee  we  over  een  periode  van  21  dagen  5FU  aan  de  muis  konden 
toedienen (Hoofdstuk 3). Wij waren een van de eerste groepen die op deze 
manier continue infusen bij muizen konden bestuderen. De plasma spiegels 
bleken in de lage micromolair range te zijn, vergelijkbaar bij patiënten die 
een 2 tot 3 weken infuus kregen. Daarnaast konden we aantonen dat de 
plasma  spiegels  in  de  muis  een  dag-nacht  ritme  vertoonden,  een  zgn. 
circadiaan variatie. Dit bleek gerelateerd te zijn aan een circadiane variatie in 
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de activiteit van dihydropyrimidine dehydrogenase (DPD), een enzym wat een 
belangrijke rol in de afbraak van 5FU speelt.
Ook de combinatie van 5FU met leucovorin werd in dit model system 
onderzocht. Helaas bleek deze combinatie, evenals bij de patiënt, te leiden 
tot een verhoogde maag-darm toxiciteit (diarree, overgeven), maar werd de 
antitumor  werking  niet  verbeterd.  Dit  kon  verklaard  worden  met  de 
bevinding dat leucovorin bij een continu infuus met 5FU de remming van 
thymidylaat synthase (TS) in de tumor niet versterkt, omdat door middel van 
een continu infuus de belangrijkste metaboliet van 5FU, FdUMP, continue 
gevormd wordt en als zodanig TS kon blijven remmen. Het leek er echter wel 
op dat leucovorin de remming van TS in normaal weefsel versterkte en dus 
tot meer bijwerkingen leidde.
Het continue infuus werd in verschillende tumor types onderzocht en 
er  werden vergelijkbare  resultaten als  bij  patiënten gevonden;  een sterke 
remming van de tumor groei, maar de overleving werd niet verbeterd. Het 
bleek dat de remming van TS synchroon liep met de tumor groei, zowel bij 
een continu infuus als de bolus injectie. Op het moment dat de tumor weer 
ging groeien nam de activiteit van TS weer toe, en werd zelfs meerdere malen 
hoger dan voor behandeling.
Omdat de bolus behandeling met 5FU in een eerdere studie een goede 
corelatie  liet  zien  tussen  de  blootstelling  aan  5FU en  de  hematologische 
toxiciteit, hebben we onderzocht of we deze relatie op een eenvoudige manier 
zouden kunnen onderzoeken (Hoofdstuk 5). De farmacologische parameter 
voor blootstelling, de “oppervlakte onder de curve” (AUC), bleek gerelateerd te 
zijn aan de bijwerkingen. Omdat voor het berekenen van de AUC echter veel 
bloedmonsters nodig zijn, hebben we onderzocht of ook volstaan kan worden 
met een of twee bloedmonsters, een zogenaamde gelimiteerde bloedafname 
(“limited sampling”). Inderdaad bleek dat plasma spiegels na 30 min de AUC 
nauwkeurig konden voorspellen. Deze benadering werd vervolgens toegepast 
bij een patiënt met een onverwacht hoge toxiciteit van 5FU, zelfs bij een lage 
dosering. Het bleek dat deze patiënt een 8-voudige afname in DPD activiteit 
had,  zodat  de  plasma  spiegels  sterk  toenamen,  leidend  to  ernstige 
bijwerkingen.  Deze  studie  toont  aan  dat  met  slechts  een  of  twee 
bloedmonsters deze patiënten gediagnosticeerd zouden kunnen worden. Een 
eenvoudige  bloedtest  zou  een  therapeutisch  volgen  (“Therapeutic  Drug 
Monitoring”)(TDM) mogelijk maken.
5FU  lijkt  op  normaal  in  het  lichaam  voorkomende  stoffen,  zoals 
uridine en thymidine. Om die reden wordt het een antimetaboliet genoemd. 
Uridine  en thymidine  zijn  belangrijke  bouwstenen  van  respectievelijk  het 
RNA en DNA, de dragers van onze genetische informatie. 5FU remt de tumor 
groei door het remmen van de RNA functie en de DNA synthese. Dit betekent 
dat  de  werking  van 5FU beïnvloed zou kunnen worden door  de  normale 
bouwstenen aan de patiënt te geven. Om die reden hebben we onderzocht of 
de werking van 5FU door het toedienen van uridine beïnvloed zou kunnen 
worden (Hoofdstuk 6 tot 9). De achterliggende gedachte was dat de inbouw 
van 5FU in RNA van normale  weefsels  verantwoordelijk  zou zijn voor  de 
bijwerkingen. Het was eerder door ons aangetoond dat het remmen van TS 
(leidend tot een vermindering van thymidine nucleotides) verantwoordelijk is 
voor  het  antitumor effect.  Daarom werd onderzocht  of  het  toedienen van 
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uridine  de  incorporatie  van 5FU in  RNA zou beinvloeden zonder  dat  het 
antitumor effect verminderd zou worden. Bovendien werd verwacht dat het 
geven van uridine bescherming (“rescue”) het ook mogelijk zou maken om 
een hogere dosis van 5FU te geven. In model systemen bleek het concept te 
werken; in muizen kon de dosering van 5FU bijna 2 maal verhoogd worden 
en  hiermee  werd  ook  het  antitumor  effect  verbeterd.  Helaas  ging  het 
toedienen van uridine in proefdieren en patiënten gepaard met koorts. Het 
veranderen  van  het  toedieningschema  (een  langdurig  infuus  van  3-uur, 
alternerend met 3 uur zonder uridine, over een periode van 72 uur), evenals 
een orale toediening bleken effectief  in het voorkomen van koorts. Omdat 
uridine een slechte orale biologische beschikbaarheid heeft (een lage opname 
uit de darm in het lichaam), hebben we onderzocht of wij een “prodrug” van 
uridine konden gebruiken, in de vorm van UDP-glucose (UDPG). UDPG kan 
gebruikt worden als een glucose donor in de biosynthese van glycogeen in de 
lever, maar UDPG wordt ook snel afgebroken tot uridine.
In  muizen  hebben  we  onderzocht  of  UDPG  in  staat  is  om  te 
beschermen tegen 5FU bijwerkingen (Hoofdstuk 7). Als we UDPG 2 uur na 
5FU gaven,  konden  we  de  dosering  van  5FU verhogen  van  100  tot  150 
mg/kg, waarbij de bijwerkingen van 5FU verminderd waren en de antitumor 
werking verbeterd. Zowel de hematologische als maag-darm toxiciteit werden 
verminderd.  Bij  een standaard dosis  van 100 mg/kg werd het  antitumor 
effect van 5FU ook niet beïnvloed. De afbraak van UDPG bleek te leiden to 
vergelijkbare plasma spiegels, zoals gevonden na de toediening van uridine 
zelf. Mechanistisch gezien bleek het toedienen van UDPG in combinatie met 
5FU  te  leiden  tot  een  verhoogde  remming  van  TS,  die  ook  nog  langer 
aanhield (Hoofdstuk 8). Verder bleek dat 5FU sneller uit het RNA verwijderd 
werd,  zonder  dat  het  antitumor  effect  beïnvloed  werd  (Hoofdstuk  9). 
Momenteel  is  een  andere  prodrug  van  uridine  (uridine  triacetate) 
geregistreerd  als  een  “orphan  drug”  met  als  indicatie  het  toedienen  bij 
patiënten  met  een  onverwachte  hoge  toxiciteit,  zoals  vaak  gevonden  bij 
patiënten met een lage of deficiënte DPD activiteit.
Ofschoon 5FU al meer dan 50 jaar gebruikt wordt voor de behandeling 
van kanker, bleek zijn metabolisme ons nog steeds voor nieuwe raadsels te 
plaatsen. Dit ingewikkelde metabolisme bleek echter een belangrijke pion te 
zijn in het verbeteren van de antitumor activiteit. 5FU vormt een onmisbaar 
standaard  onderdeel  in  de  behandeling  van  dikke  darm  kanker,  en  de 
toediening in combinatie van oxaliplatin (FOLFOX) of irinotecan (FOLFIRI) 
wordt nog steeds geoptimaliseerd. Zo zijn we inmiddels toe aan de nieuwste 
variant mFOLFOX6. Daarom is het aan te bevelen om de dosering van 5FU 
zoveel mogelijk te verbeteren, wat bereikt zou kunnen worden door middel 
van “Therapeutic Drug Monitoring”. Dit geldt ook voor de orale toediening 
van  5FU,  in  Europa  en  de  USA  meestal  in  de  vorm  van  Capecitabine 
(Xeloda®, maar in een aantal Aziatische landen meestal als UFT of S-1. S-1 
is momenteel ook in Europa en de USA geregistreerd, maar vooralsnog alleen 
voor  de  behandeling  van  maagkanker  in  combinatie  met  cisplatin.  De 
toedieningwijzen  beogen  een  continu  infuus  na  te  bootsen,  waaraan 
leucovorin  niet  meer  wordt  toegevoegd  vanwege  onaanvaardbare 
bijwerkingen.  De  rol  van  5FU  in  de  combinaties  met  nieuw  antisignaal 
transductie remmers  (zowel  antilichamen als  tyrosine  kinase  remmers)  is 
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nauwelijks  onderzocht  en  behoeft  nog  een  duidelijke  mechanistische 
onderbouwing, zoals die wel in andere tumortypes is gevonden.
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